Gland Pharma Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/aamjmv6e3zyg5hn5cx66we4x.pdf

Key Takeaways


The Supply Chain Breakdown

Srinivas Sadu: "I must say it is a tough start to FY'23 with few supply chain issues, which were ongoing for the last couple of quarters, hit us hard on a quarterly dispatches."

Demand: Strong Where It Could Be Served

Srinivas Sadu: "Primarily it's a supply chain issue... The good aspect is that the demand stays strong."

Margin Resilience & Cost Absorption

Srinivas Sadu: "I would say, it is one of the toughest quarters in terms of everything, right, I mean, the costs of utilities are high, power shortages in our states are very high, so we have to use utility for that. And then, we have to airlift lot of goods because of the shortages of materials. So that has been absorbed. So I would say, the worst things have already happened."

US Market: Launches, Pricing & Portfolio Shift


Supply-Chain Fixes in Progress


Strategic Build-Out: Biologics CDMO, Complex Injectables & China

Srinivas Sadu: "What happens with this is initially, people want to test waters, right, I mean, these are all new businesses we're entering, new technology we're entering. So they would like to give us smaller contracts for a year or so or it could be a project-based thing. And some of these gets converted to commercial scale after they do the clinicals and they come back to us for phase-III clinical batches and stuff like that."

Guidance & Commitments

CommitmentSpecificsTimeline
Supply-chain normalizationAPI and primary packing material shortages to relaxNext couple of quarters
Syringe supply normalizationBD capacity additions online; delivery schedules for current quarter in handSeptember 2022 (BD capacity online)
Heparin stopper supplyWest schedule for resolution; alternative being sought soonerNovember 2022
Dundigal production recoveryLost production from line shutdowns covered through improved productivityNext three quarters
RoW inventory normalizationReturn to normalized inventory levelsAnother quarter
Micafungin supply resumptionCustomer inventory liquidation to reverseA quarter or so
China first revenueTwo products in clearance phaseQ3 or Q4 FY23
Biologics CDMO first revenueFirst dollar possible if discussions go well; not meaningful near-termLast quarter FY23 (possible, if discussions go well)
Full-year CAPEX₹300 crores on microsphere/combi line, complex injectables, API capacity, bag lineFY23
Full-year margins (ex-other-income)Expected around current quarter's rangeFY23
Two-year margin target (ex-other-income)33–35% overall, driven by complex approvals and operating leverage on new linesNext two years
Biologics CDMO operational cost run rate₹15 crores per quarterNext one to two years
R&D spendRemain around 4% of revenueOngoing
Fosun relationshipNo change in strategic view; Gland operates independently, no inter-company depositsOngoing

Key Metrics

MetricQ1 FY23
Revenue from operations₹856.9 cr, declined 26% YoY
Gross margin56%, improvement of 284 bps YoY
EBITDA₹344.3 cr, EBITDA margin of 37%
Core EBITDA margin31.5%
Net profit₹229.2 cr, PAT margin of 25%
Other income₹74.4 cr, includes forex gains of ₹34.2 cr and interest on fixed deposits of ₹37.6 cr
Effective tax rate25.7%
Cash flow from operations₹332.9 cr
Cash and equivalents₹3,789.2 cr as on June 30, 2022
Total CAPEX incurred₹41.4 cr; full-year guidance maintained at ₹300 cr
R&D expenditure₹41 cr, 4.8% of revenue; ex-capital R&D at 4.1% of revenue
US market revenue growth~4% QoQ, degrowth of 4% YoY
Core markets revenue share82% of Q1 FY23 revenue vs 65% in Q1 FY22
Rest of the world markets revenue share12% of Q1 FY23 revenue vs 19% in Q1 FY22
India market revenue share6% of Q1 FY23 revenue
Profit share as percentage of revenue~10%
Cash conversion cycle241 days, same as Q1 FY22
ROCE (ex-cash basis)21%
ANDA filings in the US316 as on June 30, 2022
Product registrations globally1,567 as on June 30, 2022
ANDA filings completed during Q1 FY236
Product SKUs launched during Q1 FY2314
Biologics CDMO operational cost in P&L₹15 cr for the quarter; expected quarterly run rate for next one to two years
Power and fuel cost increase53% YoY, 36% QoQ
Manpower cost increase22% YoY; staff cost at ₹98 cr, confirmed as normalized base
Estimated sales loss from supply disruptions~₹250 cr in the quarter, difficult to recover 100%
Enoxaparin US sales~₹160 cr in Q1 FY23 vs ~₹47 cr in Q4 FY22
Full-year margin guidance (ex-other-income)Around current quarter's range; next two years target 33% to 35%